Undisclosed anti-PD-1 antibody
/ Premier Biomedical, University of Texas at El Paso
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 09, 2023
Tailoring Treatment Selection for Various Stages of NSCLC: Optimizing Patient Outcomes : Episode 14: Pros and Cons of Immunotherapy in Metastatic NSCLC
(AJMC)
- "Specialists assess the pros and cons of using immunotherapy in managing metastatic non-small cell lung cancer and delve into dosage variations and considerations when choosing different immunotherapy types."
Video
1 to 1
Of
1
Go to page
1